The complement system effectively identifies and clears invasive pathogens as well as injured host cells. Uncontrolled complement activation can also contribute to tissue injury, however, and inhibition of this system may ameliorate many types of inflammatory injury. Several studies have demonstrated that the filtration of complement proteins into the renal tubules, as occurs during proteinuric renal disease, causes tubular inflammation and injury. In the present study, we tested the hypothesis that activation of the complement system in the urinary space requires an intact alternative pathway. Using a model of adriamycin-induced renal injury, which induces injury resembling focal segmental glomerulosclerosis, we examined whether mice deficient in factor B would be protected from the development of progressive tubulointerstitial injury. Complement activation was attenuated in the glomeruli and tubulointerstitium of mice with congenital deficiency of factor B (fB-/-) compared with wild-type controls, demonstrating that complement activation does occur through the alternative pathway. Deficiency in factor B did not significantly protect the mice from tubulointerstitial injury. However, treatment of wild-type mice with an inhibitory monoclonal antibody to factor B did delay the development of renal failure. These results demonstrate that complement activation in this nonimmune complex-mediated model of progressive renal disease requires an intact alternative pathway.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1152/ajprenal.00403.2006 | DOI Listing |
Aim: The Transorbital and supraorbital minimally invasive approaches have been defined to reach intraorbital structures, adjacent sinuses, skull base, and other intracranial targets in this region. These approaches reduce the possible cosmetic and brain retraction-related morbidities caused by traditional transcranial approaches. Although these pathways are being studied endoscopically, a stereotactic approach has not been defined.
View Article and Find Full Text PDFAdv Healthc Mater
January 2025
Stomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou, 510280, P. R. China.
The rapid and efficient bone regeneration is still in unsatisfactory outcomes, demonstrating alternative strategy and molecular mechanism is necessary. Nanoscale biomaterials have shown some promising results in enhancing bone regeneration, however, the detailed interaction mechanism between nanomaterial and cells/tissue formation is not clear. Herein, a molecular-based inorganic-organic nanomaterial poly(citrate-siloxane) (PCS) is reported which can rapidly enhance osteogenic differentiation and bone formation through a special interaction with the cellular surface communication network factor 3 (CCN3), further activating the Wnt10b/β-catenin signaling pathway.
View Article and Find Full Text PDFPhys Chem Chem Phys
January 2025
School of Chemistry and Chemical Engineering, Guangzhou University, Guangzhou 510006, P. R. China.
Electrocatalytic oxidation of 5-hydroxymethylfurfural (HMF) to 2,5-furandicarboxylic acid (FDCA) is a promising alternative for oxygen evolution reactions. The search for efficient catalysts has been attracting increasing scientific attention. This work explores the performance of nitrogen-doped graphene-supported single-atom catalysts (M-NC SACs) for the reaction.
View Article and Find Full Text PDFFront Plant Sci
January 2025
School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, China.
is a well-known plant used in oriental medicine plant, and is also serves as the primary traditional source of plant red dyestuffs. With the current depletion of natural resources of , it is critical to conduct cultivation studies on the . Here, we report on the dynamic growth characteristics and secondary metabolite accumulation of cultivated , as well as the discovery of important genes involved in anthraquinone biosynthesis.
View Article and Find Full Text PDFAntib Ther
January 2025
Biologics Innovation Institute, Shanghai Jemincare Pharmaceutical Co., Ltd., Lane 535, Huanqiao Road, Pudong New Area, Shanghai 201315, China.
Background: Therapeutic antibody drugs targeting the PD-1 pathway are generally characterized by relatively low response rates and susceptibility to drug resistance during clinical application. Therefore, there is an urgent need for alternative therapeutic strategies to increase the immune response rate. Bispecific antibodies co-targeting PD-1 and PD-L1 may have greater potential to improve the efficacy of the immune checkpoint pathway.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!